Treatment of acne vulgaris with the retinoic acid derivative Ro 11-1430. A controlled clinical trial against retinoic acid.
In a double-blind, randomized, group-comparative clinical trial, 31 patients with acne vulgaris received topical treatment for 6-8 weeks with a lotion containing either 0.05% retinoic acid or 0.1% of the retinoic acid derivative Ro 11-1430. The side-effects erythema, desquamation and burning were significantly less frequent with Ro 11-1430 than with retinoic acid. The treatments appeared to be approximately equally effective in reducing the number of acne elements, but due to the limited number of patients studied, the trial was admittedly not sufficient to detect differences with regard to therapeutic efficacy.
D000152:Acne Vulgaris / Q000188:drug therapy*; D000287:Administration, Topical; D002986:Clinical Trials as Topic; D003875:Drug Eruptions; D004341:Drug Evaluation; D004890:Erythema / Q000139:chemically induced; D006801:Humans; D014212:Tretinoin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014801:Vitamin A / Q000031:analogs & derivatives*
D014801:Vitamin A; D014212:Tretinoin; C010832:motretinide